Dr. Frederick Wilson

Biography

Frederick Wilson graduated from Duke University with a PhD and received his MD from Harvard Medical School. He completed an internship and residency at Brigham and Women's Hospital, followed by a fellowship in medical oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital. Dr. Wilson's research primarily focuses on the identification and characterization of genetic vulnerabilities in cancer, particularly aiming to understand the genetic determinants of sensitivity and resistance to targeted therapies. A significant area of his work includes the characterization of RASGRF1 fusions as an oncogenic driver in lung cancers. His research team has identified recurrent gene fusions involving the guanine exchange factor RASGRF1 in non-small cell lung cancer and other cancers, demonstrating that these fusions activate RAS signaling and promote tumorigenesis. Additionally, he investigates the therapeutic potential of inhibiting the PRMT5 pathway in cancers with MTAP loss, which occurs in approximately 15% of malignancies. Dr. Wilson also conducts research into the resistance mechanisms to targeted therapies in lung cancer, with a focus on novel genetic drivers of resistance. His translational research is aimed at identifying new drug targets and opportunities for therapeutic combinations to overcome resistance to treatment.

Research Interests